Issa Mohamed Khairie 4

What Happened

• Issa Mohamed Khairie, EVP and Head of U.S. Oncology at Incyte Corp (INCY), received a grant/award of 14,237 derivative shares/options on January 16, 2026. The Form 4 reports the acquisition price as $0 (i.e., recorded as an award rather than an open‑market purchase or sale). No immediate sale was reported.

Key Details

• Transaction date: 2026-01-16; Report filed: 2026-01-21.
• Amount: 14,237 derivative shares/options; reported acquisition price: $0; total reported value: $0.
• Shares owned after the transaction: not disclosed in the provided excerpt of the filing.
• Footnote: Beginning January 16, 2026, the options become exercisable in 37 installments — the first 25% vests on July 15, 2026, with the remainder vesting monthly over three years.
• Filing timeliness: The Form 4 was filed five days after the transaction date; Form 4s are generally due within two business days, so this filing appears to have been submitted after the usual two‑business‑day window.

Context

• This was an award of derivative securities (options) with a vesting/exercise schedule, not a market purchase or sale. Such grants are common as executive compensation and do not by themselves indicate an insider buying or selling stock. The award becomes exercisable over time per the vesting schedule noted in the footnote.